
APPROVED
DRUG PRODUCTS



APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 4

APRIL 1998

CONTENTS

BLANK PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 4
APRIL 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

NO APPLICANT NAME CHANGES - APRIL 1998

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices.

These files may be accessed on the Internet's World Wide Web. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

BLANK

PAGE

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711		
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)		
MULTISOURCE	7052 (73.3%)	7117 (73.3%)		
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)		
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)		
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)		
NEW MOLECULAR ENTITIES APPROVED	--	8		
NUMBER OF APPLICANTS	551	529		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACARBOSE

TABLET; ORAL
PRECOSE

[redacted]		25MG	[redacted]
		25MG	N20482 004 MAY 29, 1997

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

[redacted]	[redacted]	[redacted]	[redacted]
AA	WATSON LABS	300MG;15MG	DEC 28, 1994
AA		300MG;30MG	N89998 001 DEC 28, 1994
AA		300MG;60MG	N89999 001 DEC 28, 1994

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001 AUG 28, 1992
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001 MAR 13, 1998

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;7.5MG	N40201 001 FEB 27, 1998
AA		500MG;10MG	N40201 002
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	
[redacted]		[redacted]	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	
[redacted]		[redacted]	
AA	WATSON LABS	500MG;2.5MG	MAR 04, 1996 N40122 001
AA		500MG;5MG	MAR 04, 1996 N40123 004
AA		500MG;7.5MG	MAR 04, 1996 N40123 001
AA		650MG;7.5MG	MAR 04, 1996 N40123 002
AA		650MG;10MG	MAR 04, 1996 N40122 002
AA		750MG;7.5MG	MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	HALSEY	500MG;5MG	N40219 001 JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

[redacted]	[redacted]	[redacted]	[redacted]
AA	WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

[redacted]	[redacted]	[redacted]	[redacted]
AA	WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

[redacted]				[redacted]
AA	WATSON LABS	650MG;65MG		N40139 001 DEC 16, 1996

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

> ADD >	AT	B BRAUN	250MG/100ML	N18161 001
> DLT >	AT	[redacted]	[redacted]	[redacted]

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

> ADD >	AB	CHELSEA LABS	200MG	N75101 001 APR 15, 1998
> ADD >				
> ADD >	AB	GENPHARM	200MG	N74977 001 APR 13, 1998
> ADD >				

TABLET; ORAL
ACYCLOVIR

	AB	COPLEY PHARM	400MG	N75021 001 MAR 18, 1998
	AB		800MG	N75021 002 MAR 18, 1998
> ADD >	AB	GENPHARM	400MG	N74976 001 APR 13, 1998
> ADD >				
> ADD >	AB		800MG	N74976 002 APR 13, 1998
> ADD >				
	[redacted]	[redacted]	[redacted]	[redacted]
	●		200MG	N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

> ADD >	AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001 APR 30, 1998
> ADD >				

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL		N74897 001 FEB 27, 1998
AP		EQ 1GM BASE/VIAL		N74897 002 FEB 27, 1998

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	HI TECH PHARMA	EQ 0.5% BASE		N74543 001 JAN 15, 1998

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML		N74749 001 JAN 30, 1998
[redacted]	[redacted]	[redacted]		[redacted]
	●	EQ 2MG BASE/5ML		N74302 001 SEP 30, 1994

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	GENEVA PHARMS	2MG		N74909 001 MAR 25, 1998
[redacted]	[redacted]	[redacted]		[redacted]
[redacted]		[redacted]		[redacted]
[redacted]		[redacted]		[redacted]
AB	WATSON LABS	0.25MG		N74479 001 JAN 21, 1997
AB		0.5MG		N74479 002 JAN 21, 1997
AB		1MG		N74479 003 JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL
AP BEDFORD 0.5MG/ML N74815 001 JAN 20, 1998
PROSTIN VR PEDIATRIC
AP + PHARMACIA AND UPJOHN 0.5MG/ML N18484 001
[redacted]

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
SYMMETREL
>DLT> [redacted]
>ADD> AA + ENDO PHARMS 50MG/5ML N16023 002

TABLET; ORAL
SYMMETREL
[redacted]
+ 100MG N18101 001

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT
>DLT> [redacted]
>ADD> + WYETH AYERST 0.1% N18498 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE
[redacted]
AB WATSON LABS EQ 5MG ANHYDROUS;50MG N73334 001 JUL 19, 1991

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
CORDARONE
>ADD> AB + WYETH AYERST 200MG N18972 001
>ADD> DEC 24, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
>ADD> PACERONE
>ADD> AB UPSHER SMITH 200MG N75135 001
>ADD> APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL
[redacted]
AB WATSON LABS 10MG;2MG [redacted] OCT 17, 1991
AB 10MG;4MG N73009 001 OCT 17, 1991
AB 25MG;2MG N73008 001 OCT 17, 1991
AB 25MG;4MG N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%
>ADD> @ B BRAUN 40MEQ/100ML N85734 001
>DLT> [redacted]

AMRINONE LACTATE

INJECTABLE; INJECTION
INOCOR
[redacted]
+ EQ 5MG BASE/ML N18700 001 JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA
[redacted]
+ GENSIA AUTOMEDICS 0.05MG/ML N20420 001 SEP 12, 1997

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN
AA WATSON LABS 325MG;4.5MG;0.38MG N40255 001 FEB 27, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR
[redacted]
WARNER LAMBERT EXPOR EQ 10MG BASE DEC 17, 1996
EQ 20MG BASE N20702 002 DEC 17, 1996
+ EQ 40MG BASE N20703 003 DEC 17, 1996

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE
[redacted]
AT AKORN 500 UNITS/GM; 10,000 UNITS/GM N64028 001 JAN 30, 1995
POLYSPORIN
>DLT> >DLT> [redacted]

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
POLYSPORIN
>ADD> >ADD> AT + MONARCH PHARMS 500 UNITS/GM; 10,000 UNITS/GM N61229 001

BACLOFEN

TABLET; ORAL
BACLOFEN
[redacted]
AB WATSON LABS 10MG N73092 001 JAN 28, 1994
AB 20MG N73093 001 JAN 28, 1994

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR
[redacted]
+ 300MG N19002 002 DEC 28, 1990
@ 400MG N19002 003 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
[redacted]
@ EQ 0.1% BASE N70053 001 JUN 10, 1986

> ADD > BRINZOLAMIDE

> ADD > SUSPENSION/DROPS; OPHTHALMIC
> ADD > AZOPT
> ADD > + ALCON 1% N20816 001
> ADD > APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL
BROMOCRIPTINE MESYLATE
AB LEK PHARM EQ 2.5MG BASE N74631 001
JAN 13, 1998

PARLODEL
AB + NOVARTIS EQ 2.5MG BASE N17962 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
> ADD > B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML;
> ADD > 120MG/100ML;330MG/100ML;
> ADD > 88MG/100ML N19864 001
> ADD > JUN 10, 1993
> DLT > [redacted]
> DLT >
> DLT >
> DLT >

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
> ADD > B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML;
> ADD > 74MG/100ML;640MG/100ML;500MG/100ML;
> ADD > 74MG/100ML N19867 001
> ADD > DEC 20, 1993
> DLT > [redacted]
> DLT >
> DLT >
> DLT >

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER
> ADD > AP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML;
> ADD > 860MG/100ML N18256 001
> ADD > AP 33MG/100ML;5GM/100ML;30MG/100ML;
> ADD > 860MG/100ML N20000 001
> ADD > APR 17, 1992
> DLT > [redacted]
> DLT >
> DLT >
> DLT >

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
> ADD > @ B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;
> ADD > 600MG/100ML;310MG/100ML N17510 001
> DLT > [redacted]
> DLT >

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
> ADD > B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML;
> ADD > 640MG/100ML;500MG/100ML;
> ADD > 74MG/100ML N19718 001
> ADD > SEP 29, 1989
> DLT > [redacted]
> DLT >
> DLT >
> DLT >

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER
[redacted]

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION/CARDIAC
PLEGISOL IN PLASTIC CONTAINER
+ ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 33MG/100ML;30MG/100ML; 860MG/100ML N18721 001 NOV 09, 1982
AP 33MG/100ML;30MG/100ML; 860MG/100ML N20002 001 APR 17, 1992
AP [redacted]

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER
AT B BRAUN 33MG/100ML;30MG/100ML; 860MG/100ML N18156 001
AP [redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N19632 001 FEB 29, 1988
● 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18023 001
AP [redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
[redacted]

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER
AT B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18681 001 DEC 27, 1982
AP [redacted]

CAPECITABINE

TABLET; ORAL
XELODA
ROCHE 150MG N20896 001 APR 30, 1998
+ 500MG N20896 002 APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL
[redacted]
AB WATSON LABS 12.5MG N74451 001 FEB 13, 1996
AB 25MG N74451 002 FEB 13, 1996
AB 50MG N74451 003 FEB 13, 1996
AB 100MG N74451 004 FEB 13, 1996

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

*	[redacted]	200MG	[redacted]	> ADD >	
*		300MG	[redacted]	> ADD >	
+	SHIRE	200MG	N20712 001 SEP 30, 1997	> ADD >	
+		300MG	N20712 002 SEP 30, 1997	> ADD >	

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AB	[redacted]	350MG	[redacted]	
AA	WATSON LABS	350MG	N40152 001 DEC 03, 1996	

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

AB	MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998	> DLT >	
AB		EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998	> DLT >	
AB		EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998	> ADD >	
AB		EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998	> ADD >	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	FUJISAWA	EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998	
AP		EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998	

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME

AB	ASTRA	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998		
AP		EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998		
AP		EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998		

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

KEFLEX

*	[redacted]	[redacted]	[redacted]	
@		EQ 100MG BASE/ML	N50406 003	
+		EQ 100MG BASE/ML	N62117 001	

CHLORAMPHENICOL

CAPSULE; ORAL

CHLOROMYCETIN

AB	* [redacted]	[redacted]	[redacted]		
	*	[redacted]	[redacted]		
AB	+ PARKEDALE	250MG	N60591 002		
	+	50MG	N60591 001		
	+	100MG	N60591 003		

OINTMENT; OPHTHALMIC

CHLOROMYCETIN

AB	* [redacted]	1%	[redacted]	
AT	+ PARKEDALE	1%	N50156 001	

POWDER FOR RECONSTITUTION; OPHTHALMIC

CHLOROMYCETIN

*	[redacted]	[redacted]	[redacted]	
+	PARKEDALE	25MG/VIAL	N50143 001	

SOLUTION/DROPS; AURICULAR (OTIC)

CHLOROMYCETIN

+	PARKEDALE	0.5%	N50205 001	

SOLUTION/DROPS; OPHTHALMIC

OPHTHOCHLOR

				> DLT >
AB	[redacted]	[redacted]	[redacted]	

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC

OPHTHOCHLOR

> ADD >	AT	PARKEDALE	0.5%		N61220 001

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

	*	PARKE DAVIS	[redacted]	[redacted]

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

	*	PARKE DAVIS	[redacted]	[redacted]
	+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

	*	PARKE DAVIS	[redacted]	[redacted]
	*	PARKEDALE	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLOROMYCETIN

AN	*	PARKE DAVIS	[redacted]	[redacted]
AP	+	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL

LIBRITABS

	+	ICN	5MG	N85482 001
			10MG	N85481 001
			25MG	N85488 001
	*	ROCHE	[redacted]	[redacted]
			[redacted]	[redacted]
			[redacted]	[redacted]

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

AB		ICN	5MG	N85461 001
AB			10MG	N85472 001
AB	+		25MG	N85475 001
[redacted]		ROCHE	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]	*		[redacted]	[redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIDEX

[redacted]	*	[redacted]	[redacted]	[redacted]
AT	+	ZILA	0.12%	N19028 001 AUG 13, 1986

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

[redacted]		HOSPIRA	[redacted]	[redacted]
	*		25MG/ML	N89563 001 APR 15, 1988

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

[redacted]		ROXANE LABS	[redacted]	[redacted]
AA		WATSON LABS	500MG	N81040 001 AUG 22, 1989

CHOLESTYRAMINE

POWDER; ORAL

LOCHOLEST

> ADD >	AB	ECN	EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996

CHOLESTYRAMINE

POWDER; ORAL
LOCHOLEST
> ADD > AB EON EQ 4GM RESIN/SCOOPFUL N74561 002 AUG 15, 1996
> ADD
> DLT > ● EQ 4GM RESIN/PACKET [redacted]
> DLT >
> DLT > ● EQ 4GM RESIN/SCOOPFUL [redacted]
> DLT >
LOCHOLEST LIGHT
> ADD > AB EON EQ 4GM RESIN/PACKET N74562 001 AUG 15, 1996
> ADD >
> ADD > AB EQ 4GM RESIN/SCOOPFUL N74562 002 AUG 15, 1996
> ADD >
> DLT > ● EQ 4GM RESIN/PACKET [redacted]
> DLT >
> DLT > ● EQ 4GM RESIN/SCOOPFUL [redacted]
> DLT >

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC
CILOXAN
+ ALCON EQ 0.3% BASE N20369 001 MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
CIPRO HC
+ BAYER EQ 0.2% BASE;1% N20805 001 FEB 10, 1998

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE
AA MORTON GROVE EQ 0.5MG BASE/5ML N74863 001 MAR 13, 1998

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN 3
+ PHARMACIA AND UPJOHN EQ 2% BASE N50680 002 MAR 02, 1998

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
[redacted] [redacted] [redacted] [redacted]
● EQ 150MG BASE/ML N62913 001 OCT 20, 1988

SOLUTION; TOPICAL
CLEOCIN T
[redacted] [redacted] [redacted] [redacted]
● EQ 1% BASE N62363 001 FEB 08, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL
> ADD > AB MYLAN 25MG N74947 001 APR 30, 1998
> ADD >
> ADD > AB 50MG N74947 002 APR 30, 1998
> ADD >
> ADD > AB 75MG N74947 003 APR 30, 1998
> ADD >

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M
[redacted] [redacted] [redacted] [redacted]
+ PARKEDALE EQ 150MG BASE/VIAL N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
> DLT > [redacted] [redacted] [redacted]
> DLT > [redacted] [redacted] [redacted]
> ADD > ● PARKEDALE 25 UNITS/VIAL N08317 002

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH

> ADD > ● PARKEDALE 40 UNITS/VIAL N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROLOM

AT BAUSCH AND LOMB 4% N74443 002 JAN 30, 1995

[redacted] [redacted] [redacted]

> ADD > CROMOLYN SODIUM
> ADD > AT ADV REMEDIES 4% N74706 001 APR 29, 1998
> ADD >

OPTICROM

AT + ALLERGAN 4% N18155 001 OCT 03, 1984

[redacted] [redacted] [redacted]

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

[redacted] [redacted] [redacted] [redacted]

AB WATSON LABS 10MG N74436 001 NOV 30, 1994

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

+ MERCK 0.5MG/VIAL N50682 001

[redacted] [redacted] [redacted] [redacted]

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN

> DLT > [redacted] [redacted] [redacted]
> DLT >

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN

> ADD > + PHARMACIA AND UPJOHN 10,000 IU/ML N20287 004 JAN 30, 1998
> ADD >

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL PRESERVATIVE FREE

+ BEDFORD EQ 20MG BASE/VIAL N50731 001 JAN 30, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

> ADD > + ORGANON 0.15MG;0.02MG N20713 001 APR 22, 1998
> ADD >
> ADD >

DESOXIMETASONE

OINTMENT; TOPICAL
DESOXIMETASONE

> ADD > AB ALTANA 0.25% N73440 001 APR 01, 1998
> ADD >

DEXAMETHASONE SODIUM PHOSPHATE

[redacted] [redacted]
[redacted]

[redacted] [redacted] [redacted] [redacted]
● EQ 0.1MG PHOSPHATE/INH N13413 001

[redacted] [redacted]
[redacted]

[redacted] [redacted] [redacted] [redacted]
● EQ 0.1MG PHOSPHATE/INH N14242 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

> ADD > AP B BRAUN 10GM/100ML N18046 001

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

> DLT >	AP	[redacted]	[redacted]	[redacted]	
		DEXTROSE 5% IN PLASTIC CONTAINER			
> ADD >	AP	B BRAUN	5GM/100ML	N16730	001
> ADD >	AP		50MG/ML	N16730	002
> DLT >	AP	[redacted]	[redacted]	[redacted]	[redacted]
> DLT >	AP		[redacted]	[redacted]	[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;		
> ADD >		26MG/100ML;320MG/100ML	N19873	001
> ADD >			JUN 10,	1993
> DLT >	[redacted]	[redacted]	[redacted]	
> DLT >		[redacted]	[redacted]	[redacted]
> DLT >			[redacted]	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;		
> ADD >		220MG/100ML;140MG/100ML	N19844	001
> ADD >			JUN 10,	1993
> DLT >	[redacted]	[redacted]	[redacted]	
> DLT >		[redacted]	[redacted]	[redacted]
> DLT >			[redacted]	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;		
> ADD >			370MG/100ML;530MG/100ML;		
> ADD >			500MG/100ML	N19843	001
> ADD >				AUG 09,	1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

> DLT >	AP	[redacted]	[redacted]	[redacted]	
> DLT >			[redacted]		
> DLT >			[redacted]	[redacted]	[redacted]
> DLT >				[redacted]	[redacted]

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;		
> ADD >			370MG/100ML;530MG/100ML;		
> ADD >			500MG/100ML	N18274	001
> DLT >	AP	[redacted]	[redacted]	[redacted]	
> DLT >			[redacted]		
> DLT >			[redacted]	[redacted]	[redacted]

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	5GM/100ML;75MG/100ML	N18744	001
> ADD >				NOV 09,	1982
> DLT >	AP	[redacted]	[redacted]	[redacted]	
> DLT >				[redacted]	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;		
> ADD >		280MG/100ML;91MG/100ML	N19870	001
> ADD >			JUN 10,	1993
> DLT >	[redacted]	[redacted]	[redacted]	
> DLT >		[redacted]	[redacted]	[redacted]
> DLT >			[redacted]	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> ADD >	@ B BRAUN	10GM/100ML;900MG/100ML	N18047	001
> DLT >	# [redacted]	[redacted]	[redacted]	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> ADD >	@ B BRAUN	5GM/100ML;900MG/100ML	N18026	001

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> DLT >	# [redacted]	[redacted]	[redacted]		

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

[redacted]	[redacted]	[redacted]	[redacted]		
	●	5MG/ML	N72371 001 JAN 29, 1993		

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]		
	●	20MG	N84600 001 JUL 29, 1985		

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	ALTANA	0.05%	N75187 001 MAR 30, 1998		
	PSORCON				
AB	+ DERMIK LABS	0.05%	N20205 001 NOV 20, 1992	> ADD > > ADD >	
[redacted]	[redacted]	[redacted]	[redacted]		

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002 MAR 18, 1998		
AB2		180MG	N75124 003 MAR 18, 1998		

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB2	MYLAN	240MG	N75124 001 MAR 18, 1998		
	TIAZAC				
[redacted]	[redacted]	[redacted]	[redacted]		
		360MG	N20401 005 SEP 11, 1995		

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998		
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998	> ADD > > ADD >	

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]		
	●	12.5MG/5ML	N83237 001 JAN 25, 1982		

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP	BEDFORD	5MG/ML	N74939 001 APR 13, 1998	> ADD > > ADD >	

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001 FEB 18, 1998		
AP		EQ 12.5MG BASE/ML	N74995 001 MAR 31, 1998		

> ADD > DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > COSOPT
> ADD > + MERCK — EQ 2% BASE;EQ 0.5% BASE — N20869 001 APR 07, 1998
> ADD >

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	
AB		[redacted]	
AB	WATSON LABS	EQ 10MG BASE	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001 MAR 29, 1991
AB		EQ 50MG BASE	N72987 001 MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

AP	[redacted]	[redacted]	[redacted]
AP		[redacted]	
		[redacted]	
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	APR 13, 1989
AP		50MG/VIAL	N62926 002 APR 13, 1989
		100MG/VIAL	N62926 003 APR 13, 1989

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP	ABBOTT	10MG/ML	N40131 001 FEB 24, 1998

ENCAINIDE HYDROCHLORIDE

[redacted]

	[redacted]	[redacted]	[redacted]
		[redacted]	
●		25MG	N18981 002 DEC 24, 1986
●		35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

+	RHONE POULENC RORER	40MG/0.4ML	N20164 002 JAN 30, 1998
+		60MG/0.6ML	N20164 003 MAR 27, 1998
+		80MG/0.8ML	N20164 004 MAR 27, 1998
+		100MG/ML	N20164 005 MAR 27, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

[redacted]	[redacted]	[redacted]	[redacted]
AT	AKORN	0.5%	N64830 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

[redacted]	[redacted]	[redacted]	[redacted]
+	HEALTHPOINT	2%	N50584 001 JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

[redacted]	[redacted]	[redacted]	[redacted]
AB		333MG	N60272 002
[redacted]	ERY-TAB [redacted]	[redacted]	[redacted]

ERYTHROMYCIN

TABLET, DELAYED RELEASE; ORAL
ERY-TAB

AB	+ ABBOTT	250MG	N62298 001	
AB		[redacted]	[redacted]	
AB	+	333MG	N62298 003	MAR 29, 1982
AB		[redacted]	[redacted]	
AB	+	500MG	N62298 002	

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB	[redacted]	1MG	[redacted]	
AB		2MG	[redacted]	
AB	WATSON LABS	1MG	N74818 001	AUG 19, 1997
AB		2MG	N74818 002	AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA

BX	+ BERLEX	0.075MG/24HR	N20375 003	MAR 23, 1998

TABLET; ORAL
ESTRADIOL

AB	ENDEAVOR	0.5MG	N40138 001	JAN 30, 1998
AB		1MG	N40138 002	JAN 30, 1998
AB		2MG	N40138 003	JAN 30, 1998

ESTRONE

INJECTABLE; INJECTION
THEELIN

[redacted]		[redacted]	[redacted]	
●	PARKEDALE	1MG/ML	N03977 001	
●		2MG/ML	N03977 002	
●		5MG/ML	N03977 003	

ESTRONE

INJECTABLE; INJECTION
THEELIN

[redacted]		[redacted]	[redacted]	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVORA 0.15/30-21

AB	[redacted]	[redacted]	[redacted]	
AB	WATSON LABS	0.03MG;0.15MG	N73592 001	DEC 13, 1993

TABLET; ORAL-28
LEVORA 0.15/30-28

AB	[redacted]	[redacted]	[redacted]	
AB	WATSON LABS	0.03MG;0.15MG	N73594 001	DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

AB	[redacted]	[redacted]	[redacted]	
AB	SEARLE	0.035MG;1MG	N71400 001	APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/35E-28

AB	[redacted]	[redacted]	[redacted]	
AB	SEARLE	0.035MG;1MG	N71401 001	APR 12, 1988

ETODOLAC

CAPSULE; ORAL
ETODOLAC

	AB	AESGEN	300MG	N74929 001 JAN 30, 1998
> ADD >	AB	TARO	200MG	N75078 001
> ADD >				APR 30, 1998
> ADD >	AB		300MG	N75078 002
> ADD >				APR 30, 1998

TABLET; ORAL
ETODOLAC

> ADD >	AB	CHELSEA LABS	400MG	N75069 001
> ADD >				APR 16, 1998
	AB	MYLAN	400MG	N75104 001 FEB 06, 1998
	AB	NOVEX LABS	400MG	[redacted]
	AB	TARO	400MG	N75074 001 MAR 11, 1998
	AB	WATSON LABS	400MG	N74892 001 APR 16, 1997

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

	+	WYETH AYERST	500MG	N20584 003 JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

	AP	MARSAM	20MG/ML	N74968 001 JAN 09, 1998

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

	*	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	[redacted]

ETOPOPHOS PRESERVATIVE FREE

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996
	+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998

FENFLURAMINE HYDROCHLORIDE

TABLET; ORAL
[redacted]

	*	[redacted]	[redacted]	[redacted]
	●		20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL

	●	ABBOTT	100MG	N19304 001 DEC 31, 1993
	*	[redacted]	[redacted]	[redacted]

TRICOR (MICRONIZED)

	+	ABBOTT	67MG	N19304 002 FEB 09, 1998

FENTANYL CITRATE

INJECTABLE; INJECTION
[redacted]

AP		[redacted]	[redacted]	[redacted]
AP	*	[redacted]	[redacted]	[redacted]

FENTANYL CITRATE PRESERVATIVE FREE

AP		ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991
AP	+	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984
AP		MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998

[redacted]

AP	*	[redacted]	[redacted]	[redacted]

SUBLIMAZE PRESERVATIVE FREE

AP	+	JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FLOSEQUINAN

TABLET; ORAL
[redacted]

		[redacted]	50MG	[redacted]

FLOSEQUINAN

[redacted]

	[redacted]	[redacted]	[redacted]	[redacted]
	[redacted]	[redacted]		[redacted]
	●		50MG	N19960 001 DEC 30, 1992
	●		75MG	N19960 002 DEC 30, 1992
	●		100MG	N19960 003 DEC 30, 1992

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL

>DLT>	[redacted]	[redacted]	[redacted]	[redacted]
>DLT>				[redacted]
>ADD>	AP	+	50MG/ML	N81225 001
>ADD>				AUG 28, 1991

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

>ADD>	AO	KING PHARMS	25MG/ML	N74966 001
>ADD>				APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

>DLT>	[redacted]		
>DLT>	[redacted]		
>DLT>	[redacted]	[redacted]	[redacted]
>ADD>	●	0.05%;EQ 3.5MG BASE/GM	N50346 001
>DLT>	[redacted]		
>DLT>	[redacted]		
>DLT>	[redacted]	[redacted]	[redacted]
>ADD>	●	0.05%;EQ 3.5MG BASE/GM	N50345 001

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX

[redacted]	[redacted]	[redacted]
	25MG	N20243 001 DEC 05, 1994

GEMFIBROZIL

CAPSULE; ORAL
LOPID

	[redacted]	[redacted]	[redacted]
●	PARKE DAVIS PHARMS	200MG	N18422 001
●		300MG	N18422 002

TABLET; ORAL
LOPID

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB	+	PARKE DAVIS PHARMS	600MG	N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>ADD>	AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 60MG BASE/100ML	N62814 009
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 70MG BASE/100ML	N62814 010
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 0.8MG BASE/ML	N62814 001
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 80MG BASE/100ML	N62814 011
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 90MG BASE/100ML	N62814 012
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 100MG BASE/100ML	N62814 013
>ADD>				AUG 28, 1987
>ADD>	AP		EQ 1.2MG BASE/ML	N62814 002
>ADD>				AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987	
> ADD >	AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987	
> ADD >	AP		EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987	
> ADD >	AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987	
> ADD >	AP		EQ 2MG BASE/ML	N62814 006 AUG 28, 1987	
> ADD >	AP		EQ 2.4MG BASE/ML	N62814 007 [illegible]	
> DLT >	AP	MCGAW	EQ 40MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 60MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 70MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 0.8MG BASE/ML	[illegible]	
> DLT >	AP		EQ 80MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 90MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 100MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 1.2MG BASE/ML	[illegible]	
> DLT >	AP		EQ 120MG BASE/100ML	[illegible]	
> DLT >	AP		EQ 1.4MG BASE/ML	[illegible]	
> DLT >	AP		EQ 1.6MG BASE/ML	[illegible]	
> DLT >	AP		EQ 1.8MG BASE/ML	[illegible]	
> DLT >	AP		EQ 2MG BASE/ML	[illegible]	
> DLT >	AP		EQ 2.4MG BASE/ML	[illegible]	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOSPORIN

> DLT >	AT	+ GLAXO WELLCOME	[illegible]	[illegible]
> DLT >				
> ADD >	AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001
> ADD >				

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HCL

AB	ROYCE LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997
AB	WATSON LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	PUREPAC PHARM	0.5MG	[illegible]
AB		1MG	[illegible]
AB		2MG	[illegible]
AB		5MG	[illegible]
AB		10MG	[illegible]
AB		20MG	[illegible]
	@	0.5MG	N71071 001 NOV 03, 1986
	@	1MG	N71072 001 NOV 03, 1986
	@	2MG	N71073 001 NOV 03, 1986
	@	5MG	N71074 001 NOV 03, 1986

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

	@ PUREPAC PHARM	10MG	N71075 001 AUG 04, 1987
	@	20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	BEDFORD	EQ 50MG BASE/ML	N74811 001 JAN 30, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	MARSAM	[redacted]	[redacted]
AP		[redacted]	[redacted]
	@	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
	@	EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
	@	200 UNITS/100ML	N19042 001 MAR 29, 1985
AP	MCGAW	[redacted]	[redacted]
	@	[redacted]	[redacted]

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ MCGAW	[redacted]	[redacted]

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985
	@ MCGAW	[redacted]	[redacted]

HEPARIN SODIUM 20,000 UNITS in DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992
AP	MCGAW	[redacted]	[redacted]

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	@	5,000 UNITS/100ML	N19134 001 MAR 29, 1985
AP	MCGAW	[redacted]	[redacted]
AP		[redacted]	[redacted]
	@	[redacted]	[redacted]

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	@	10,000 UNITS/100ML	N19802 002 JUL 20, 1992
	@ MCGAW	[redacted]	[redacted]
	@	[redacted]	[redacted]

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	@	5,000 UNITS/100ML	N19802 003 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ MCGAW	5,000 UNITS/100ML	[illegible] [illegible]
@	5,000 UNITS/100ML	[illegible] [illegible]

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
@ MCGAW	1,000 UNITS/100ML	[illegible] [illegible]

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVAPRO HCT

@ SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
+	12.5MG;150MG	N20758 002 SEP 30, 1997

IRBESARTAN-HYDROCHLOROTHIAZIDE

@ SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
+	12.5MG;150MG	N20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

> ADD >	AB	INVAMED	15MG;250MG	N70829 001 MAR 09, 1987
> ADD >	AB		25MG;250MG	N70830 001 MAR 09, 1987
> DLT >		@	15MG;250MG	N70829 001 MAR 09, 1987
> DLT >		@	25MG;250MG	N70830 001 MAR 09, 1987

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N74970 0(JAN 06, 19(

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

NOVARTIS	12.5MG;80MG	N20818 00 MAR 06, 199
+	12.5MG;160MG	N20818 00 MAR 06, 199

HYDROCORTISONE

CREAM; TOPICAL
ANUSOL HC

> DLT >	AT	PARKE DAVIS	2.5%	N88250 001
> DLT >				JUN 06, 1984
> ADD >	AT	PARKEDALE	2.5%	N88250 001
> ADD >				JUN 06, 1984

SOLUTION; TOPICAL
TEXACORT

> DLT >	AT	+ GENDERM	1%	N80425 001
> ADD >	AT	+ MEDICIS	1%	N80425 001

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREMYD

> ADD >	+ AKORN	1%;0.25%	N19261 001
> ADD >			JAN 30, 1992
> DLT >	+ ALLERGAN	1%;0.25%	N19261 001
> DLT >			JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	[illegible]	[illegible]	[illegible] [illegible]

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB		WATSON LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL
DROXIA

		BRISTOL MYERS SQUIBB	200MG	N16295 002 FEB 25, 1998
			300MG	N16295 003 FEB 28, 1998
	◆		400MG	N16295 004 FEB 25, 1998

HYDREA

AB	◆	BRISTOL MYERS SQUIBB	500MG	N16295 001
AB	※	SQUIBB	[redacted]	[redacted]

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

[redacted]		ROXCH LABS	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
AB		WATSON LABS	10MG	MAR 18, 1994
AB			25MG	N81150 001 MAR 18, 1994
AB			50MG	N81151 001 MAR 18, 1994

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL

[redacted]		AM HOME PRODS	[redacted]	[redacted]
BX		WHITEHALL ROBINS	100MG/5ML	N19833 002 SEP 19, 1989

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

AB		ALPHARMA	100MG/5ML	N74978 001 MAR 25, 1998

MOTRIN

AB	◆	MCNEIL	100MG/5ML	N19842 001 SEP 19, 1989
[redacted]	※		[redacted]	[redacted]

TABLET; ORAL
IBUPROFEN

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
	●		400MG	[redacted] JAN 14, 1988
	●		600MG	N72055 001 JAN 14, 1988
	●		800MG	N71938 001 JAN 14, 1988

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB		TEVA	1.25MG	N74498 002 FEB 12, 1998

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL

AP		ELKINS SINN	51%	N74629 004 MAR 31, 1998

IOPAMIDOL-250

AP		ABBOTT	51%	N75005 001 FEB 24, 1998

IOPAMIDOL-300

AP		ABBOTT	61%	N75005 002 FEB 24, 1998

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-370

AP		ABBOTT	76%	N75005 003 FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 190

	[redacted]	[redacted]	[redacted]
	BERLEX LABS	40.6%	N19580 001 DEC 07, 1989

OSMOVIST 240

	[redacted]	[redacted]	[redacted]
	BERLEX LABS	51.3%	N19580 002 DEC 07, 1989

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT

	[redacted]	[redacted]	[redacted]
+		0.018MG/INH	N19085 001 DEC 29, 1986

ISOSULFAN BLUE

INJECTABLE; INJECTION
LYMPHAZURIN

	[redacted]	[redacted]	[redacted]
+	US SURGCL	1%	N18310 001

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
			[redacted]	[redacted]
AP	+	PARKEDALE	EQ 50MG BASE/ML	N16812 002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

AP	+	PARKEDALE	EQ 100MG BASE/ML	N16812 003
	+		EQ 10MG BASE/ML	N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
		100MG	N19816 003 FEB 08, 1995
		150MG	N19816 002 FEB 08, 1995

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN

+	HOECHST MARION ROUSS	50MG/VIAL	N20807 001 MAR 06, 1998

LIDOCAINE; PRILOCAINE

DISC; TOPICAL
EMLA

+	ASTRA	2.5%;2.5%	N20962 001 FEB 04, 1998

LORAZEPAM

TABLET; ORAL
LORAZEPAM

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
[redacted]		[redacted]	[redacted]

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	WATSON LABS	0.5MG	N72926 001	OCT 31, 1991
AB		1MG	N72927 001	OCT 31, 1991
AB		2MG	N72928 001	OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

+	PHARMOS	0.2%	N20803 001 MAR 09, 1998

LOTEMAX

+	PHARMOS	0.5%	N20583 001 MAR 09, 1998
+		0.5%	N20841 001 MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C

> DLT >	*	COCENSYS	EQ 25MG BASE/ML	N17658 001
> ADD >	+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION
LOXITANE IM

> DLT >	*	COCENSYS	EQ 50MG BASE/ML	N18039 001
> ADD >	+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

> DLT >	AB		COCENSYS	[illegible]	N17523 001
> DLT >	AB			[illegible]	N17523 002
> DLT >	AB	*		[illegible]	N17523 003
> DLT >	AB			[illegible]	N17523 004
> ADD >	AB		WATSON LABS	[illegible]	N17525 001
> ADD >	AB			[illegible]	N17525 002
> ADD >	AB	+		[illegible]	N17525 003

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

> ADD >	AB		WATSON LABS	EQ 50MG BASE	N17525 004

TABLET; ORAL
LOXITANE

> DLT >	*	COCENSYS	EQ 10MG BASE	[illegible]
> DLT >	*		EQ 25MG BASE	[illegible]
> DLT >	*		EQ 50MG BASE	[illegible]
> ADD >		WATSON LABS	EQ 10MG BASE	N17525 006
> ADD >			EQ 25MG BASE	N17525 007
> ADD >			EQ 50MG BASE	N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	BERTEK PHARMS	EQ 85MG BASE/GM	N16763 001
*	MEDA PHARMA	EQ 85MG BASE/GM	[illegible]

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

> ADD >	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001 SEP 29, 1989
> DLT >	MCGAW	[illegible]	[illegible]

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989	
> DLT >	AP	MCGAW	[illegible]	[illegible]	
> DLT >					
> ADD >	AP	B BRAUN	5GM/100ML	N16772 002	
> DLT >		MCGAW	[illegible]	[illegible]	

MALATHION

LOTION; TOPICAL
OVIDE

@ GENDERM	0.5%	[illegible]	
@ MEDICIS	0.5%	N18613 001 AUG 02, 1982	

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	10GM/100ML	N20006 002 JUL 26, 1993
> DLT >	AP	MCGAW	[illegible]	[illegible]
		MANNITOL 15% IN PLASTIC CONTAINER		
> ADD >	AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993
> DLT >	AP	MCGAW	[illegible]	[illegible]
		MANNITOL 20%		
> ADD >	AP	B BRAUN	20GM/100ML	N14738 001
> DLT >	AP	MCGAW	[illegible]	[illegible]
		MANNITOL 20% IN PLASTIC CONTAINER		
> ADD >	AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993
> DLT >	AP	MCGAW	[illegible]	[illegible]
		MANNITOL 5% IN PLASTIC CONTAINER		
> ADD >	AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION
MANNITOL 5% IN PLASTIC CONTAINER

> DLT >	AP	MCGAW	[illegible]	[illegible]
> DLT				[illegible]

SOLUTION; IRRIGATION
RESECTISOL IN PLASTIC CONTAINER

> ADD >		B BRAUN	5GM/100ML	N16772 002
> DLT >		MCGAW	[illegible]	[illegible]

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE

+	LAYTON	2.5MG	N10251 001
+	MERCK SHARP DOHME	2.5MG	[illegible]

NEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA	BOYCE LABS	50MG	[illegible]
AA	WATSON LABS	50MG	N40186 001 JUN 30, 1997

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21

AB	ROBERTS LABS	[illegible]	[illegible]
AB	SEARLE	0.05MG;1MG	N71539 001 APR 12, 1988

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	ROBERTS LABS	[illegible]	[illegible]	
AB	SEARLE	0.05MG;1MG	N71540 001	APR 12, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

> ADD > AA	ROXANE	10MG/ML	N40180 001	APR 30, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	EON	40MG	N75082 001	MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL

AP	MYLAN	100MG/ML	[illegible]	
	@	100MG/ML	N89849 001	DEC 27, 1991

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	[illegible]	EQ 5MG BASE	[illegible]	
AB		EQ 10MG BASE	[illegible]	
	@	EQ 5MG BASE	N72436 001	JUN 22, 1989
	@	EQ 10MG BASE	N70850 001	FEB 03, 1987

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

> ADD > AB	DANBURY PHARMA	150MG	N74865 001	APR 13, 1998
> ADD > AB		200MG	N74865 002	APR 13, 1998
> ADD > AB		250MG	N74865 003	APR 13, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

> ADD > AP	SUPERGEN	MG/VIAL	N64144 001	APR 30, 1998
> ADD > AP		20MG/VIAL	N64144 002	APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAIR

+	MERCK	EQ 10MG BASE	N20829 002 FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

+	MERCK	EQ 5MG BASE	N20830 001 FEB 20, 1998

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998
AP		20MG/ML	N74471 002	MAR 19, 1998

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	LOYCH LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+ SYNTEX	375MG	N20067 002 OCT 14, 1994
AB	+	500MG	N20067 003 OCT 14, 1994

NAPROXEN

AB	INVAMED	375MG	N75061 001 FEB 18, 1998
AB		500MG	N75061 002 FEB 18, 1998
AB	PUREPAC PHARM	375MG	N74936 001 FEB 24, 1998
AB		500MG	N74936 002 FEB 24, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	AL HIKMA	EQ 250MG BASE	N74480 002 FEB 18, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

	GLAXO WELLCOME	EQ 1MG BASE	N20763 002 FEB 10, 1998
	+	EQ 2.5MG BASE	N20763 001 FEB 10, 1998

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

AT	GLAXO WELLCOME	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001
AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION

	+ INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HCL

AB	GENPHARM	20MG	N74928 001 MAR 19, 1998
AB		30MG	N74928 002 MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

AB	3M	0.1MG/HR	N89771 002 AUG 30, 1996
AB1		0.1MG/HR	N89771 001 AUG 30, 1996
AB		0.2MG/HR	N89772 002 AUG 30, 1996
AB1		0.2MG/HR	N89772 001 AUG 30, 1996
AB		0.4MG/HR	N89773 002 AUG 30, 1996
AB1		0.4MG/HR	N89773 001 AUG 30, 1996
AB		0.6MG/HR	N89774 002 AUG 30, 1996
AB1		0.6MG/HR	N89774 001 AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MITRO-DUR

[redacted]		[redacted]	[redacted]	
AB1	+	0.1MG/HR	N20145 001	APR 04, 1995
[redacted]		[redacted]	[redacted]	
AB1	+	0.2MG/HR	N20145 002	APR 04, 1995
[redacted]		[redacted]	[redacted]	
AB1	+	0.4MG/HR	N20145 004	APR 04, 1995
[redacted]		[redacted]	[redacted]	
AB1	+	0.6MG/HR	N20145 005	APR 04, 1995

NITROGLYCERIN

AB2		MYLAN	0.1MG/HR	N75033 001 FEB 06, 1998
[redacted]			[redacted]	[redacted]
AB2			0.2MG/HR	N74609 001 AUG 30, 1996
[redacted]			[redacted]	[redacted]
AB2			0.4MG/HR	N74607 001 AUG 30, 1996
[redacted]			[redacted]	[redacted]
AB2			0.6MG/HR	N74559 001 AUG 30, 1996

TRANSDERM-NITRO

AB2	+	NOVARTIS	0.1MG/HR	N20144 001 FEB 27, 1996
[redacted]			[redacted]	[redacted]
AB2	+		0.2MG/HR	N20144 002 FEB 27, 1996
[redacted]			[redacted]	[redacted]
AB2	+		0.4MG/HR	N20144 003 FEB 27, 1996
[redacted]			[redacted]	[redacted]

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

TRANSDERM-NITRO

AB2	+	NOVARTIS	0.6MG/HR	N20144 004 FEB 27, 1996
[redacted]			[redacted]	[redacted]

NORETHINDRONE

TABLET; ORAL

NOR-QD

[redacted]		[redacted]	[redacted]	[redacted]
AB	+	WATSON LABS	0.35MG	N17060 001

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

	+	ASTRA MERCK	40MG	N19810 002 JAN 15, 1998

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

AA	+	ALZA	5MG/5ML	N18211 001
[redacted]		[redacted]	[redacted]	[redacted]

TABLET; ORAL

DITROPAN

>ADD<	AB	+	ALZA	5MG	N17577 001
>DLT<	[redacted]		[redacted]	[redacted]	[redacted]

OXYTOCIN

INJECTABLE; INJECTION

PITOCIN

>DLT<	[redacted]		[redacted]	[redacted]	[redacted]
>ADD<	AP	+	PARKEDALE	10 USP UNITS/ML	N18261 001

> ADD > PARICALCITOL

> ADD > INJECTABLE; INJECTION
> ADD > ZEMPLAR
> ADD > + ABBOTT 0.005MG/ML N20819 001
> ADD > APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
> DLT > AB + PARKE DAVIS EQ 250MG BASE N60521 001
> DLT > AB EQ 250MG BASE N62310 001
> ADD > AB + PARKEDALE EQ 250MG BASE N60521 001
> ADD > AB EQ 250MG BASE N62310 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON
> ADD > + ALZA 100MG N20193 001
> ADD > SEP 26, 1996
> DLT > + BAKER NORTON 100MG N20193 001
> DLT > SEP 26, 1996

PERMETHRIN

CREAM; TOPICAL
ELIMITE
AB + ALLERGAN 5% N19855 001
AUG 25, 1989

PERMETHRIN
AB ALPHARMA 5% N74806 001
JAN 23, 1998

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN
* ROCHE 50MG;500MG N19358 001
AUG 31, 1990

@ 50MG;500MG N19358 001
AUG 31, 1990

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE
AP BEDFORD 5MG/VIAL N40235 001
MAR 11, 1998

REGITINE
AP + NOVARTIS 5MG/VIAL N08278 003

PINDOLOL

TABLET; ORAL
PINDOLOL
AB PUREPAC PHARM 5MG N74125 001
APR 28, 1993
AB 10MG N74125 002
APR 28, 1993
@ 5MG N74125 001
APR 28, 1993
@ 10MG N74125 002
APR 28, 1993
AB ROXCH LABS 5MG N74437 001
FEB 27, 1995
AB 10MG N74437 002
FEB 27, 1995
AB WATSON LABS 5MG N74437 001
FEB 27, 1995
AB 10MG N74437 002
FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER
+ LEDERLE EQ 40MG BASE/ML;
EQ 5MG BASE/ML N50750 001
FEB 24, 1998
+ EQ 4GM BASE/100ML;
EQ 500MG BASE/100ML N50750 003
FEB 24, 1998
+ EQ 60MG BASE/ML;
EQ 7.5MG BASE/ML N50750 002
FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM
[redacted]

AB WATSON LABS 10MG N74460 001
SEP 29, 1995
AB 20MG N74460 002
SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
[redacted]

@ 236GM/BOT;2.97GM/BOT;6.74GM/BOT;
5.86GM/BOT;22.74GM/BOT N73098 001
AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
[redacted]
@ EQ 500,000 U BASE/VIAL N62036 001
POLYMYXIN B SULFATE
[redacted]
AP + EQ 500,000 U BASE/VIAL N60716 001

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
> ADD > AT ALCON 10,000 UNITS/ML;
> ADD > EQ 1MG BASE/ML N64211 001
> ADD > APR 13, 1998

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
> ADD > AP B BRAUN [redacted] N85870 001
> DLT > [redacted]

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
> ADD > @ B BRAUN 75MG/100ML;900MG/100ML N18722 001
> ADD > NOV 09, 1982
> DLT > [redacted]
> DLT >
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
> ADD > @ B BRAUN 150MG/100ML;900MG/100ML N18722 002
> ADD > NOV 09, 1982
> DLT > [redacted]
> DLT >
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
> ADD > @ B BRAUN 220MG/100ML;900MG/100ML N18722 003
> ADD > NOV 09, 1982
> DLT > [redacted]
> DLT >
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
> ADD > @ B BRAUN 300MG/100ML;900MG/100ML N18722 004
> ADD > NOV 09, 1982
> DLT > [redacted]
> DLT >

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
PHARMACIA AND UPJOHN 0.5MG N20667 006
FEB 12, 1998

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE
[redacted]

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

RX	+	DANBURY PHARMA	5MG	N80354 001
RX	*	GENEVA PHARMS	5MG	N80339 001
	@		5MG	N80339 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE

	+	ELAN PHARMA	250MG/5ML	N10401 001
	*	WYETH AYERST	250MG/5ML	N10401 001

TABLET; ORAL
MYSOLINE

AB	+	ELAN PHARMA	250MG	N09170 002
	+		50MG	N09170 003
AB	*	WYETH AYERST	250MG	N09170 002
	*		50MG	N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB		ENDURAMED	500MG	N89284 001 JUN 23, 1986
	@		500MG	N89284 001 JUN 23, 1986

PROCAN SR

> DLT >	AB	PARKE DAVIS	500MG	N86065 001
> DLT >	AB		750MG	N87510 001 APR 01, 1982
> DLT >	AB	*	1GM	N88489 001 JAN 16, 1985
> DLT >				
> ADD >	AB	PARKEDALE	500MG	N86065 001
> ADD >	AB		750MG	N87510 001 APR 01, 1982
> ADD >	AB	+	1GM	N88489 001 JAN 16, 1985
> ADD >				

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	NAESAN	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988
@		EQ 5MG BASE/ML	N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	TRIGEN	EQ 5MG BASE	N40268 001 FEB 27, 1998
AB		EQ 10MG BASE	N40268 002 FEB 27, 1998
AB	ZENITH GOLDLINE	EQ 5MG BASE	N40162 001 JAN 20, 1998
AB		EQ 10MG BASE	N40162 002 JAN 20, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	NAESAN	25MG/ML	N89463 001 MAY 02, 1988
AP		50MG/ML	N89477 001 MAY 02, 1988
@		25MG/ML	N89463 001 MAY 02, 1988
@		50MG/ML	N89477 001 MAY 02, 1988

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	PUREPAC PHARM	65MG	N83278 001
@		65MG	N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	[redacted]	[redacted]	[redacted]		
AB		[redacted]			
AB		[redacted]			
AB		[redacted]			
AB		[redacted]			
AB		[redacted]			
	●	10MG	[redacted] JUL 05, 1988	> ADD >	
	●	20MG	N71687 001 JUL 05, 1988	> ADD >	
	●	40MG	N71688 001 JUL 05, 1988	> ADD >	
	●	60MG	N72197 001 JUL 05, 1988		
	●	80MG	N71689 001 JUL 05, 1988		
	●	90MG	N72198 001 JUL 05, 1988		

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	[redacted]	[redacted]	[redacted]		
	●	200MG	N84003 001		

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

	[redacted]	[redacted]	[redacted] DEC 30, 1988	> ADD >	
	+	EQ 15MG BASE/ML	N19675 001 DEC 30, 1988	> ADD >	

TABLET; ORAL
RANITIDINE HCL

AB	RANBAXY	EQ 150MG BASE	N75000 001 JAN 30, 1998		

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	RANBAXY	EQ 300MG BASE	N75000 002 JAN 30, 1998		

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

	+	PROCTER AND GAMBLE	30MG	N20835 001 MAR 27, 1998	

SACROSIDASE

SOLUTION; ORAL
SUCRAID

	+	ORPHAN MEDCL	8,500 IU/ML	N20772 001 APR 09, 1998	

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE

	[redacted]	[redacted]	[redacted]	[redacted]	
	+		200MG	N20828 001 NOV 07, 1997	

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

	ESI LEDERLE	5MG	N74641 001 AUG 02, 1996	> ADD >	
	[redacted]	[redacted]	[redacted]	> ADD >	
	[redacted]	[redacted]	[redacted]	> DLT >	
	[redacted]	[redacted]	[redacted]	> DLT >	
AB	STASON	5MG	N74912 001 APR 30, 1998	> ADD >	

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA

	PFIZER	25MG	N20895 001	
			MAR 27, 1998	
		50MG	N20895 002	
			MAR 27, 1998	
	+	100MG	N20895 003	
			MAR 27, 1998	

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	450MG/100ML	N19635 001	
> ADD >				MAR 09, 1988	
> ADD >		●	450MG/100ML	N18184 001	
> DLT >	AP	MCGAW	[illegible]	[illegible]	
> DLT >				[illegible]	
> DLT >		●	[illegible]	[illegible]	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	900MG/100ML	N17464 001	
> ADD >	AP		900MG/100ML	N19635 002	
> ADD >				MAR 09, 1988	
> DLT >	AP	MCGAW	[illegible]	[illegible]	
> DLT >	AP		[illegible]	[illegible]	
> DLT >				[illegible]	

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

> ADD >		● B BRAUN	3GM/100ML	N19635 003	
> ADD >				MAR 09, 1988	
> DLT >		● MCGAW	3GM/100ML	[illegible]	
> DLT >				[illegible]	

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

> ADD >		● B BRAUN	5GM/100ML	N19635 004	
> ADD >				MAR 09, 1988	
> DLT >		● MCGAW	5GM/100ML	[illegible]	
> DLT >				[illegible]	

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

> ADD >		● B BRAUN	1.87GM/100ML	N18186 001	
> DLT >		● MCGAW	1.87GM/100ML	[illegible]	

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

> ADD >	AP	B BRAUN	1.87GM/100ML	N20004 001	
> ADD >				APR 21, 1992	

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

> DLT >	AP	MCGAW	[illegible]	[illegible]	
> DLT >				[illegible]	

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE

AA	PADDOCK	[illegible]	[illegible]	
AA	+	453.6GM/BOT	N11287 001	
	KIONEX			
AA	PADDOCK	454GM/BOT	N40029 001	
			FEB 06, 1998	

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

	● [illegible]	120MG	[illegible]
			[illegible]
		120MG	N19865 005
			APR 20, 1994

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%

AP	+ PHARMACIA AND UPJOHN	30%	N19942 001	
			DEC 30, 1993	

LIPOSYN III 30%

AP	+ ABBOTT	30%	N20181 001	
			JAN 13, 1998	

NUTRILIPID 10%

> ADD >	AP	+ B BRAUN	10%	N19531 001
> ADD >				MAY 28, 1993
> DLT >	AP	● MCGAW	10%	[illegible]
> DLT >				[illegible]

NUTRILIPID 20%

> ADD >	AP	+ B BRAUN	20%	N19531 002
> ADD >				MAY 28, 1993
> DLT >	AP	● MCGAW	20%	[illegible]
> DLT >				[illegible]

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	*	APOTHECON	20MG/ML	[illegible]
	@		20MG/ML	N08847 001

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTA

AP	+	AKORN	EQ 0.05MG BASE/ML	N19050 001 MAY 04, 1984
AP	*	JANSSEN	EQ 0.05MG BASE/ML	[illegible]

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
SMZ-TMP

AB		TEVA	200MG/5ML;40MG/5ML	[illegible]

SMZ-TMP PEDIATRIC

AB		TEVA	200MG/5ML;40MG/5ML	[illegible]

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		TEVA	200MG/5ML;40MG/5ML	N18812 001 JAN 28, 1983
AB			200MG/5ML;40MG/5ML	N18812 002 JUN 10, 1983

TABLET; ORAL
SMZ-TMP

AB		TEVA	[illegible]	[illegible]
AB			[illegible]	[illegible]

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		TEVA	400MG;80MG	N18242 001
AB			800MG;160MG	N18242 002

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

AB		[illegible]	[illegible]	[illegible]

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

	@	SUPERPHARM	500MG	N89339 001 OCT 26, 1987

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

		[illegible]	[illegible]	[illegible]
			[illegible]	
			[illegible]	
	*		[illegible]	
		PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001 SEP 09, 1993
			EQ 20MG BASE	N20070 002 SEP 09, 1993
			EQ 30MG BASE	N20070 003 SEP 09, 1993
	+		EQ 40MG BASE	N20070 004 SEP 09, 1993

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS		DRAXIMAGE	N/A	N17881 001 DEC 30, 1987
BS		[illegible]	N/A	[illegible]

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE

AP		DRAXIMAGE	N/A	N18272 001 JAN 27, 1982
AP		[illegible]	N/A	[illegible]

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

> ADD >	DRAXIMAGE	N/A	N18489 001	
> ADD >	MERCK	N/A	OCT 31, 1986	
> DLT >			N18489 001	
> DLT >			OCT 31, 1986	

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT

AP	DRAXIMAGE	N/A	N18035 001	
AP	MERCK SHARP DOHME	N/A	N18035 001	

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

AP	DRAXIMAGE	N/A	N18511 001	
AP	MERCK	N/A	DEC 29, 1989	
			N18511 001	
			DEC 29, 1989	

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
SULFUR COLLOID

AP	CIS	N/A	N17858 001	
	●	N/A	N17858 001	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	EQ 1MG BASE	N20347 001	
AB	+	EQ 2MG BASE	DEC 14, 1994	
AB		EQ 5MG BASE	N20347 002	
AB		EQ 10MG BASE	DEC 14, 1994	
			N20347 003	
			DEC 14, 1994	
			N20347 004	
			DEC 14, 1994	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

AB	GENEVA PHARMS	EQ 1MG BASE	N74823 001	
			MAR 30, 1998	
AB		EQ 2MG BASE	N74823 002	
			MAR 30, 19..	
AB		EQ 5MG BASE	N74823 003	
			MAR 30, 1998	
AB		EQ 10MG BASE	N74823 004	
			MAR 30, 1998	

> ADD > TERBINAFINE

GEL; TOPICAL
LAMISIL

> ADD >	+ NOVARTIS	1%	N20846 001	
> ADD >			APR 29, 1998	
> ADD >				
> ADD >				

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

RX	* THERATECH	5MG/24HR	N20489 001	
			SEP 29, 1995	
	+	2.5MG/24HR	N20489 001	
			SEP 29, 1995	

THEOPHYLLINE

CAPSULE, ORAL
THEOPHYLLIN

RX	FOREST LABS	100MG	N85545 001	
			JUL 31, 1984	
RX	*	200MG	N83921 001	
			JUL 31, 1984	
	●	100MG	N85545 001	
			JUL 31, 1984	
	●	200MG	N83921 001	
			JUL 31, 1984	

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLIN SR

RC	FOREST LABS	125MG	N88826 001	
			JAN 23, 1992	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

ELIXOPHYLLIN SR

RC	FOREST LABS	250MG	[illegible]	
	@	125MG	N86826 001	
	@	250MG	JAN 29, 1985 N86826 002 JAN 29, 1985	

THIAMYLAL SODIUM

INJECTABLE INJECTION

SURITAL

*	PARKE DAVIS	1GM/VIAL	N07600 003	> ADD >	AB	
*		5GM/VIAL	N07600 005	> ADD >		
*		10GM/VIAL	N07600 009	> ADD >		
@	PARKEDALE	1GM/VIAL	N07600 003	> ADD >	AB	
@		5GM/VIAL	N07600 005	> ADD >		
@		10GM/VIAL	N07600 009	> DLT >	AB	
				> DLT >		
				> DLT >	AB	
				> DLT >		

TOLCAPONE

TABLET; ORAL

TASMAR

	ROCHE	100MG	N20697 001 JAN 29, 1998
+		200MG	N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL

DETROL

	PHARMACIA AND UPJOHN	1MG	N20771 001 MAR 25, 1998
+		2MG	N20771 002 MAR 25, 1998

TRETINOIN

CREAM; TOPICAL

AVITA

> DLT >	AB	* PENEDERM	0.025%	[illegible]		
> DLT >				JAN 14, 1997		

TRETINOIN

CREAM; TOPICAL

AVITA

> ADD >	AB	PENEDERM	0.025%	N20404 003 JAN 14, 1997		
> ADD						

GEL; TOPICAL

AVITA

	PENEDERM	0.025%	N20400 001 JAN 29, 1998

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

> ADD >	AB	ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982		
> ADD >						
> ADD >	AB		EQ 2MG BASE	N87613 001 NOV 19, 1982		
> ADD >						
> DLT >	AB	[illegible] LABS	EQ 1MG BASE	[illegible]		
> DLT >						
> DLT >	AB		EQ 2MG BASE	[illegible]		
> DLT >						

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HCL

AA	CIRCA	2MG	N40184 001 FEB 06, 1998
AA		5MG	N40184 002 FEB 06, 1998

TROGLITAZONE

TABLET; ORAL

REZULIN

AB	PARKE DAVIS	200MG	[illegible]
AB		300MG	
AB		400MG	
AB	PARKE DAVIS PHARMS	200MG	[illegible] JAN 29, 1997

TROGLITAZONE

TABLET; ORAL
REZULIN
AB PARKE DAVIS PHARMS 300MG N20720 003 AUG 04, 1997
AB 400MG N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE
> DLT > AP AKORN 1% [illegible]
> DLT >
> ADD > ● 1% N88447 001 AUG 28, 1985
> ADD >

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX
+ SERONO 75 IU/AMP N19415 002 SEP 18, 1986
+ 150 IU/AMP N19415 003 SEP 18, 1986
METRODIN
[illegible] SERONO 75 IU/AMP [illegible]
[illegible] 150 IU/AMP [illegible]

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL
AP MARSAM [illegible] [illegible]
AP [illegible] [illegible]
● 2.5MG/ML N72233 001 FEB 26, 1993
● 2.5MG/ML N73485 001 SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION
VIRA-A
[illegible] PARKE DAVIS [illegible] [illegible]
● PARKEDALE EQ 187.4MG BASE/ML N50523 001

OINTMENT; OPHTHALMIC
VIRA-A
[illegible] PARKE DAVIS [illegible] [illegible]
+ PARKEDALE 3% N50486 001

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION I'V PLASTIC CONTAINER
> ADD > AP B BRAUN 100% N19633 001 FEB 29, 1988
> ADD >
> DLT > AP [illegible] 100% [illegible]
> DLT >

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)
+ BRISTOL MYERS — 250MG;250MG;65MG — N20802 001 JAN 14, 1998 — > DLT > > DLT > > ADD > > ADD >

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON
* HOECHST MARION RSSL — 40MG;20MG — N18685 001 DEC 09, 1983
80MG;20MG — N18685 001 DEC 09, 1983
+ 160MG;40MG — N18685 002 DEC 09, 1983 — > DLT > > DLT > > ADD > > ADD >
GAVISCON-2
* HOECHST MARION RSSL — 160MG;40MG — N18685 002 DEC 09, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB
> ADD > > ADD > ECOLAB — 4% — N19258 002 JUL 22, 1986
> DLT > > DLT > HUNTINGTON LABS — 4% — N19258 002 JUL 22, 1986
CIDA-STAT
> ADD > > ADD > ECOLAB — 2% — N19258 001 JUL 22, 1986
> DLT > > DLT > HUNTINGTON LABS — 2% — N19258 001 JUL 22, 1986 — > ADD > > ADD >

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX
COPLEY PHARM — 100MG — N73249 001 FEB 13, 1998 — > ADD > > ADD >

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED
* WHITEHALL ROBINS — 100MG/5ML — N20589 002 NOV 07, 1997
100MG/5ML — N20589 002 NOV 07, 1997

SUSPENSION/DROPS; ORAL
PEDIATRIC ADVIL
+ WHITEHALL ROBINS — 100MG/2.5ML — N20812 001 JAN 30, 1998

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN
MCNEIL — 100MG — N20601 003 NOV 15, 1996
+ 100MG — N20601 003 NOV 15, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3
+ ADVANCED CARE PRODS — 4% — N20827 001 MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
NU PHARM — 2% — N74924 001 APR 29, 1998
MINOXIDIL (FOR WOMEN)
> ADD > > ADD > NU PHARM — 2% — N74924 002 APR 29, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL
* MCNEIL — 15MG/16HR — N20536 001 JUL 03, 1996
+ PHARMACIA AND UPJOHN — 15MG/16HR — N20536 001 JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75
+ GLAXO WELLCOME EQ 75MG BASE N20745 001
FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL '98

NO APRIL 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through April 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
9-cis-retinoic acid TN=	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998

Orphan Product Designations and Approvals List
January 1998 through April 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4, DD=01/06/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998

Orphan Product Designations and Approvals List
January 1998 through April 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Tangon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Recombinant humanized monclonal antibody 5c8	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998
Recombinant humanized monoclonal antibody 5c8	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Dept. of Neurology Philips Building, Suite 2Q; 10 Union Square New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998

Orphan Product Designations and Approvals List
January 1998 through April 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN

NEW INDICATION

I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	
I-219	
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C,BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731266	MAR 24, 2015	U-221		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164196	NOV 01, 2010	U-207		
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
>ADD>	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
	020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
>ADD>	020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
>ADD>				5508297	FEB 24, 2014	U-3		
>ADD>				5534534	JUL 09, 2013			
>ADD>	020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
>ADD>				5508297	FEB 24, 2014	U-3		
>ADD>				5534534	JUL 09, 2013			
>ADD>	020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
>ADD>				5508297	FEB 24, 2014	U-3		
>ADD>				5534534	JUL 09, 2013			
>ADD>	020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
>ADD>				5508297	FEB 24, 2014	U-3		
>ADD>				5534534	JUL 09, 2013			
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
	020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
	020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
	020774	001	CHLORHEXIDINE GLUCONATE;PERIO CHIP				NP	MAY 15, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
>ADD>	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
>ADD>	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
>ADD>	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	018938	001	[redacted]	5763407	DEC 23, 2013			
>ADD>	018938	002	[redacted]	5763407	DEC 23, 2013			
>ADD>	019955	001	[redacted]	5763407	DEC 23, 2013		I-40	MAR 25, 2001
>ADD>	019955	002	[redacted]	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	[redacted]				NP	APR 22, 2001
	020057	001	[redacted]				I-213	FEB 25, 2001
	020401	001	[redacted]				I-133	JAN 30, 2001
	020401	002	[redacted]				I-133	JAN 30, 2001
	020401	003	[redacted]				I-133	JAN 30, 2001
	020401	004	[redacted]				I-133	JAN 30, 2001
	020401	005	[redacted]				I-133	JAN 30, 2001
	020869	001	[redacted]				NC	APR 07, 2001
	020164	001	[redacted]				I-217	JAN 30, 2001
	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-222	MAR 27, 2001
							I-222	MAR 27, 2001
							I-217	JAN 30, 2001
	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020718	001	EPTIFIBATIDE;INTEGRILIN				NCE	MAY 18, 2003
	020718	002	EPTIFIBATIDE;INTEGRILIN				NCE	MAY 18, 2003
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	020363	001	FANCICLOVIR;FAMVIR				NCE	JUN 29, 1999
	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	APR 10, 1999			
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472582	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 1999			
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
>ADD>	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
>ADD>	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
>ADD>	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				CDE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				CDE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				CDE	FEB 25, 2005
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 14, 1998
>ADD>	020903	001	INTERFERON ALFA-2B;REBETRON				NP	JUN 03, 2001
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME		PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020406	001	LANSOPRAZOLE;PREVACID					I-227	MAR 12, 2001
	020406	002	LANSOPRAZOLE;PREVACID					I-227	MAR 12, 2001
	020807	001	LEPIRUDIN;REFLUDAN		5180668	JAN 19, 2010		ODE	MAR 06, 2005
								NCE	MAR 06, 2003
	019732	001	LEUPROLIDE	DEPOT	5716640	SEP 02, 2013			
	020011	001	LEUPROLIDE [redacted]	DEPOT	5716640	SEP 02, 2013			
	020517	001	LEUPROLIDE [redacted]	DEPOT	5716640	SEP 02, 2013			
	020263	002	LEUPROLIDE [redacted]	DEPOT-PED	5716640	SEP 02, 2013			
	020263	003	LEUPROLIDE [redacted]	DEPOT-PED	5716640	SEP 02, 2013			
	020263	004	LEUPROLIDE [redacted]	DEPOT-PED	5716640	SEP 02, 2013			
	020263	005	LEUPROLIDE [redacted]	DEPOT-PED	5716640	SEP 02, 2013			
	020263	006	LEUPROLIDE [redacted]	DEPOT-PED	5716640	SEP 02, 2013			
	020708	001	LEUPROLIDE [redacted]	DEPOT-3	5716640	SEP 02, 2013			
	020517	002	LEUPROLIDE [redacted]	DEPOT-4	5716640	SEP 02, 2013			
	019941	001	LIDOCAINE;EMLA [redacted]					I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA					NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED		5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX		4996335	FEB 26, 2008		NCE	MAR 09, 2003
					5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX		4996335	FEB 26, 2008		NCE	MAR 09, 2003
					5540930	OCT 25, 2013			
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX		4996335	FEB 26, 2008		NCE	MAR 09, 2003
					5540930	OCT 25, 2013			
>ADD>	019832	003	MAFENIDE ACETATE;SULFAMYLON					NDF	JUN 05, 2001
>ADD>								ODE	JUN 05, 2005
	019618	001	MESALAMINE;ROWASA		4657900	APR 14, 2004			
					RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL					D-40	MAY 16, 2000
	020827	001	MICONAZOLE NITRATE;MONISTAT 3					NP	MAR 30, 2001
	020762	001	MOMETASONE FUROATE MONONYDRATE;NASONEX		4472393	SEP 18, 2001			
>ADD>	020830	001	MONTELUKAST SODIUM;SINGULAIR		5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
>ADD>	020829	002	MONTELUKAST SODIUM;SINGULAR		5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE					NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE					NCE	FEB 10, 2003
	020536	001	NICOTINE;NICOTROL		4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR					I-220	APR 01, 2001
								D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN					NDF	DEC 16, 2000
	020262	001	PACLITAXEL;TAXOL					I-226	APR 09, 2001
>ADD>	020819	001	PARICALCITOL;ZEMPLAR					NCE	APR 17, 2003
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN					ODE	FEB 11, 2005
								I-212	FEB 11, 2001
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL					I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL					I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL					I-225	MAR 27, 2001
	019781	001	PROGESTERONE;PROMETRIUM					NP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN		5731355	MAR 22, 2015	U-217		
					5731356	MAR 22, 2015	U-218		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA		4418068	APR 03, 2001			
					5393763	JUL 28, 2012	U-114		
					5457117	JUL 28, 2012	U-114		
					5478847	MAR 02, 2014	U-114		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
>ADD>	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
>ADD>	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211		
>ADD>				5380922	JAN 10, 2012			
>ADD>				5590645	MAR 01, 2011			
>ADD>				5126375	FEB 12, 2008			
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
>ADD>	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
>ADD>				5658929	MAR 08, 2011			
>ADD>				5733919	OCT 23, 2016			
>ADD>	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
>ADD>				5658929	MAR 08, 2011			
>ADD>				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
>ADD>	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
>ADD>	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
>ADD>	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
>ADD>	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			

New 18th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 80128

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Thank you for your order!

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature) (11/97)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

50


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
1.0
1.1
1.25
1.4
1.6
1.8
2.0
2.2
2.5
2.8
3.2
3.6
4.0
4.5
5.0
6"